LH2PLOD2

LH2PLOD2 is a putative chimeric transcript described in certain genomic datasets as the result of transcriptional readthrough between the LH2 and PLOD2 genes. It is typically classified as a LH2–PLOD2 readthrough or fusion transcript and has been noted in RNA sequencing surveys of human tissues and some cancer samples.

The canonical LH2PLOD2 transcript is predicted to splice together exons from LH2 and PLOD2, potentially encoding a fusion protein that contains elements from both gene products. However, evidence for a stable, translated protein is limited, and some reports treat LH2PLOD2 as a nonproductive transcript.

Expression patterns reported for LH2PLOD2 appear to be low and tissue-restricted, with detections mainly in specific tissues or tumor types and often only in a subset of samples. Validation methods include RNA sequencing, RT-PCR, and targeted sequencing.

Functional interpretation remains uncertain. If translated, the fusion product could influence collagen modification pathways or cellular signaling, given the involvement of PLOD2 in extracellular matrix remodeling, but functional data are preliminary. At present, LH2PLOD2 is not established as a reliable biomarker.

Discovery and resources: LH2PLOD2 has been cataloged in some transcript databases and discussed in the context of readthrough transcription and gene fusion discovery. Further independent validation and functional studies are needed to determine its biological significance.